Estimated reading time: 6 minutes Key Takeaways The Dow Jones Industrial Average (DJIA) closed at 44,173.64 on 5 August 2025, eking out a modest gain. Large-cap technology and healthcare shares were the …
Latest in Trading News
-
-
Estimated reading time: 4 minutes Key Takeaways Dow Jones Industrial Average closed at 44,173.64, its largest single-day gain in three weeks. Technology shares spearheaded the advance, with Palantir (PLTR) jumping …
-
Estimated reading time: 6 minutes Key Takeaways The Dow Jones Industrial Average closed at 44,173.64, capping a weekly drop of 2.92%. Rising inflation expectations and policy uncertainty are pressuring equities. …
-
Estimated reading time: 4 minutes Key Takeaways Record earnings beat propels *Palantir Technologies* into fresh market highs. Wall Street’s consensus price target inches higher amid AI expansion. Analysts cite government …
-
Estimated reading time: 6 minutes Key Takeaways *Bullish* aims to raise USD 629 million through an IPO on the New York Stock Exchange. Backed by legendary investor Peter Thiel and led by former …
-
Estimated reading time: 6 minutes Key Takeaways Earnings beats are powering sharp rallies in select technology and healthcare names, while misses trigger equally swift retreats. Tariff uncertainty continues to act …
-
Estimated reading time: 6 minutes Key Takeaways Tariffs are designed to raise import prices, yet their impact on the overall U.S. trade deficit has been modest. Retaliatory duties often offset …
-
Estimated reading time: 6 minutes Key Takeaways Equity indices continue an *“everything rally,”* but experts caution about underlying risks. Global policy shifts—from tariffs to tax reforms—are reshaping corporate strategies. Cryptocurrency …
-
Estimated reading time: 6 minutes Key Takeaways Full trading session: both the New York Stock Exchange and Nasdaq operate 9:30 a.m.–4:00 p.m. ET. Pre-market buzz in technology stocks lifts futures by 0.4%. Watch …
-
Estimated reading time: 6 minutes Key Takeaways Vertex ends development of VX-548, a once-promising non-opioid analgesic. The failure underscores persistent challenges in finding effective, non-addictive pain relief. Shares dropped ~8% …